Identification and characterization of the CDK1-BMAL1-UHRF1 pathway driving tumor progression

Wang, Dan; Wang, Fenglin; Wang, Shengfeng; Chu, Ling; Tang, Daolin; Chen, Pan; Yang, Minghua

doi:10.1016/j.isci.2023.106544

Search citation statements

Order By: Relevance

Paper Sections

Select...

Methods1

Serum Mif Expression Exhibits a Distinct Circadian Rhythm1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(2 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cells in logarithmic growth phase were seeded in 6 or 12-well plates at a density of approximately 2000 cells per well [ 30 , 31 ]. Following 24 h of drug treatment, the cells were detached and cultured for an additional 10–14 days.…”

Section: Methodsmentioning

confidence: 99%

Ciprofloxacin is a novel anti-ferroptotic antibiotic

Chen,

Tang,

Lin

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Ciprofloxacin is a novel anti-ferroptotic antibiotic

Chen,

Tang,

Lin

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…Night-shift workers have higher serum MIF levels compared to day-shift workers [101], indicating that circadian disruption affects MIF expression. In addition, MIF transcription is regulated by ICBP90 (also called UHRF1) [102]; UHRF1 has been shown to be a downstream effector of BMAL1, one of the core circadian clock transcription factors [103], suggesting a potential mechanism for the circadian regulation of MIF expression.…”

Section: Serum Mif Expression Exhibits a Distinct Circadian Rhythmmentioning

confidence: 99%

MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy

Fey,

Nichols,

Tran

et al. 2024

Cancers

View full text Add to dashboard Cite

Immune checkpoint blockade (ICB) therapy is used to treat a wide range of cancers; however, some patients are at risk of developing treatment resistance and/or immune-related adverse events (irAEs). Thus, there is a great need for the identification of reliable predictive biomarkers for response and toxicity. The cytokine MIF (macrophage migration inhibitory factor) and its cognate receptor CD74 are intimately connected with cancer progression and have previously been proposed as prognostic biomarkers for patient outcome in various cancers, including solid tumors such as malignant melanoma. Here, we assess their potential as predictive biomarkers for response to ICB therapy and irAE development. We provide a brief overview of their function and roles in the context of cancer and autoimmune disease. We also review the evidence showing that MIF and CD74 may be of use as predictive biomarkers of patient response to ICB therapy and irAE development. We also highlight that careful consideration is required when assessing the potential of serum MIF levels as a biomarker due to its reported circadian expression in human plasma. Finally, we suggest future directions for the establishment of MIF and CD74 as predictive biomarkers for ICB therapy and irAE development to guide further research in this field.

show abstract